Introduction
============

Hypertension is a major public health problem, affecting approximately 1 billion worldwide.^[@bib1]^ The etiology of hypertension is not well understood because of multi-factorial causes. Hypertension can be caused by single-gene or multi-factorial conditions, resulting from interactions between the environment and inherited risk factors.^[@bib2]^ In fact, human hypertension is a condition associated with endothelial dysfunction and oxidative stress.^[@bib3],\ [@bib4]^ Mitochondrial dysfunction has been potentially implicated in both human and experimental hypertension.^[@bib5],\ [@bib6],\ [@bib7]^ Specifically, abnormal mitochondrial respiration results in oxidative stress, uncoupling of the oxidative pathways for ATP synthesis and subsequent failure of cellular energetic processes.^[@bib8]^ An inefficient metabolism caused by mitochondrial dysfunctions in skeletal and vascular smooth muscles may lead to the elevation of systolic blood pressure and, therefore, may be involved in the development of hypertension.^[@bib6],\ [@bib7],\ [@bib9],\ [@bib10]^ Maternal transmission of hypertension has been implicated in some pedigrees, suggesting that the mutation(s) in mitochondrial DNA (mtDNA) is one of the molecular bases for this disorder.^[@bib10],\ [@bib11],\ [@bib12],\ [@bib13],\ [@bib14],\ [@bib15],\ [@bib16]^ In particular, the 4295A\>G and 4263A\>G mutations in the tRNA^Ile^ gene, the 4401A\>G mutation in the junction between tRNA^Gln^ and tRNA^Met^ genes, as well as the 4435A\>G mutation in the tRNA^Met^ gene were associated with essential hypertension.^[@bib14],\ [@bib15],\ [@bib16],\ [@bib17]^

With the aim of investigating a role of the mitochondrial genome in the pathogenesis of hypertension in the Chinese population, a systematic and extended mutational screening of mtDNA has been initiated in several cohorts of essential hypertension Chinese subjects.^[@bib14],\ [@bib15],\ [@bib16],\ [@bib17]^ In the present study, we performed the clinical, genetic and molecular characterization of another Han Chinese family with suggestive maternally transmitted hypertension. Eight of 17 matrilineal relatives in this family exhibited variable severity and age-at-onset in essential hypertension, while none of the offspring of affected fathers had hypertension. Mutational analysis of the mitochondrial genome in this Chinese family identified the known tRNA^Met^ 4435A\>G mutation, which is localized at the 3′ end adjacent to the anticodon (position 37) of tRNA^Met^.^[@bib17],\ [@bib18],\ [@bib19]^ The adenine at this position of tRNA^Met^ is extraordinarily conserved from bacteria to human mitochondria. The mitochondrial genome in this Chinese family belonged to the Eastern--Asian haplogroup G2a1,^[@bib20]^ while the 4435A\>G mutation also occurs in the other mtDNA haplogroups: B5a of a Chinese family with hypertension^[@bib16]^ and D5 of a Chinese family with LHON^[@bib18]^ and a Japanese subject with diabetes.^[@bib19]^ The occurrence of the 4435A\>G mutation in these genetically unrelated subjects affected by the hypertension suggests that this mutation is involved in the pathogenesis of hypertension.

Subjects and methods
====================

Subjects
--------

As a part of a genetic screening program for hypertension, a Han Chinese family ([Figure 1](#fig1){ref-type="fig"}) was ascertained at the Hypertension Clinic of Wenzhou Medical College. Informed consent, blood samples and clinical evaluations were obtained from all participating family members, under the protocols approved by the ethics committee of Wenzhou Medical College and the Cincinnati Children\'s Hospital Medical Center Institute Review Board. Members of this family were interviewed and evaluated to identify both personal or medical histories of hypertension and other clinical abnormalities.

Clinical evaluation
-------------------

Members of this Chinese family underwent a physical examination and laboratory assessment of cardiovascular disease risk factors. A physician measured the systolic and diastolic blood pressures of subjects using a mercury column sphygmomanometer and a standard protocol.^[@bib1],\ [@bib21]^ The first and the fifth Korotkoff sounds were taken as indicative of systolic and diastolic blood pressure, respectively. The average of three such systolic and diastolic blood pressure readings was taken as the examination blood pressure. Hypertension was defined according to the recommendation of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI)^[@bib1]^ and the World Health Organization-International Society of Hypertension^[@bib21]^ as a systolic blood pressure of ≥140 mm Hg and/or a diastolic blood pressure of ≥90 mm Hg.

These subjects then underwent a heart function evaluation by electrocardiography (ECG). Signals from the first 10 s of the conventional ECG recording were analyzed automatically in software to quantify all major intervals, axes and voltages, as well as ST segment levels. Initial candidate criteria used for defining these strictly conventional 12-lead ECGs were as follows: left ventricular hypertrophy (LVH) according to traditional Sokolow--Lyon voltage criteria^[@bib22]^ (SV1+RV5 or RV6≥3.5 mV) or gender-specific Cornell voltage (RaVL+SV3≥2.8 mV in men or ≥2.0 mV in women) criteria.^[@bib23]^

Two-dimensional guided M-mode recording was performed from the parasternal window according to the guidelines of the American Society of Echocardiography. The following parameters on the M-mode echocardiogram were evaluated: left ventricular end diastolic diameter (LVDd, cm), interventricular septal diastolic thickness (IVSTd, cm), and left ventricular posterior wall diastolic thickness (LVPWTd, cm). Left ventricular mass (LVM) was calculated according to Devereux\'s adjusted formula: LVM=0.8 × 1.04 × \[(LVDd+LVPWTd+IVSTd)^3^−LVDd^3^\]+0.6 g.^[@bib24]^ Left ventricular mass index (LVMI) was defined as LVM divided by body surface area (BSA) (LVM/BSA, g/m^2^). BSA was calculated according to the formula BSA=0.6 × height (m)+0.0128 × weight (kg)−0.1529. LVMI \>125 g/m^2^ in males or \>115 g/m^2^ in females was diagnosed as LVH.

Mutational analysis of mitochondrial genome
-------------------------------------------

Genomic DNA was isolated from whole blood cells of participants using Puregene DNA Isolation Kits (Gentra Systems, Minneapolis, MN, USA). The entire mitochondrial genome of the proband II-9 was PCR amplified in 24 overlapping fragments by using sets of the light-strand and heavy-strand oligonucleotide primers, as described elsewhere.^[@bib25]^ Each fragment was purified and subsequently analyzed by direct sequencing in an ABI 3700 automated DNA sequencer (Applied Biosystems, Inc., Foster City, CA, USA) using the Big Dye Terminator Cycle sequencing reaction kit. The resultant sequence data were compared with the revised consensus Cambridge sequence (GenBank accession number: NC_012920).^[@bib26]^

For the quantification of the 4435A\>G mutation, the PCR segments (700 bp) were amplified using genomic DNA as template and oligodeoxynucleotides corresponding to mtDNA at positions 3861--4560, and subsequently digested with a restriction enzyme *Nla*III. In fact, the 4435A\>G mutation creates a novel site for this enzyme.^[@bib18]^ Equal amounts of various digested samples were then analyzed by electrophoresis through 7% polyacrylamide gel. The proportions of digested and undigested PCR products were determined by the Image-Quant program after ethidium bromide staining to observe whether the 4435A\>G mutation is in homoplasmy in these subjects.

Phylogenetic analysis
---------------------

A total of 17 vertebrate mtDNA sequences were used in the interspecific analysis. These include *Bos Taurus, Cebus albifrons, Gorilla gorilla, Homo sapiens, Hylobates lar, Lemur catta*, *Macaca mulatta*, *Macaca sylvanus, Mus musculus, Nycticebus coucang, Pan paniscus, Pan troglodytes, Pongo pygmaeus, Pongo abelii, Papio hamadryas, Tarsius bancanus,* and *Xenopus laevis* (Genbank). The conservation index (CI) was calculated by comparing the human nucleotide variants with those of other 16 vertebrates. The CI was then defined as the percentage of species from the list of 16 different vertebrates that have the wild-type nucleotide at that position.

Haplogroup analyses
-------------------

The entire mtDNA sequence of the Chinese proband carrying the 4435A\>G mutation was assigned to an Asian mitochondrial haplogroup by using the nomenclature of mitochondrial haplogroups.^[@bib20]^

Results
=======

Clinical presentation
---------------------

The proband (II-9) began suffering from hypertension at the age of 54 years. As shown in [Table 1](#tbl1){ref-type="table"}, his blood pressure was 190/110 mm Hg by then. He came to the Hypertension Clinic of Wenzhou Medical College for further clinical evaluations at the age of 60 years. After the administration of ACE inhibitor, calcium channel blocker (CCB) and diuretic, his blood pressure was 132/80 mm Hg. As shown in [Table 2](#tbl2){ref-type="table"}, laboratory assessment of cardiovascular disease risk factors showed that he had a normal range of the index of liver metabolic function, the blood routine and 24-h urinary sodium. The echocardiogram (ECG) showed that his interventricular septal and posterior ventricular wall thickness (13 mm) increased with normal atrial and ventricular dimension. Physical examination showed that he did not have other clinical abnormalities, including diabetes, visual and hearing impairments, renal and neurological disorders. Therefore, he exhibited a typical essential hypertension. The family is originated from Zhejiang Province in Eastern China. All members of this family were interviewed and/or evaluated to identify both personal and medical histories of hypertension and other clinical abnormalities. As shown in [Figure 1](#fig1){ref-type="fig"} and [Table 1](#tbl1){ref-type="table"}, 8 of 17 matrilineal relatives had a wide range of severity in hypertension (with blood pressure \>140/90 mm Hg even with treatment for hypertension), whereas only 1 of 8 nonmaternal relatives suffered from hypertension. None of the offspring of affected fathers exhibited hypertension. As shown in [Table 1](#tbl1){ref-type="table"}, the age at onset of hypertension in eight affected matrilineal relatives of the maternal kindred varied from 31 to 65 years, with an average of 52 years. However, other nine unaffected matrilineal relatives, who were below 52 years, had a tendency to develop the hypertension. There was no evidence that any member of this family had any other cause to account for hypertension. We further examined the end organ damage on the heart and kidney among nine matrilineal relatives and married-in subject II-3 of this family. As shown in [Table 1](#tbl1){ref-type="table"}, four (II-4, II-8, III-4 and III-5) matrilineal relatives exhibited myocardial ischemia on the ECG recorded, while subject III-8 suffered from segment elevation. In addition, none of eight matrilineal relatives, except the proband, exhibited an increased interventricular septal thickness. Furthermore, the clearance of endogenous creatinine and level of urea nitrogen were assessed in 9 matrilineal relatives and 10 control subjects. As shown in [Table 1](#tbl1){ref-type="table"}, the rates of endogenous creatinine clearance in nine subjects (II-3, II-4, II-6, II-8, II-9, III-1, III-4, III-5 and III-8) were below the standard levels, whereas the level of urea nitrogen among seven of nine matrilineal relatives were above the standard levels. These data implicated the presence of renal dysfunction in these patients. However, none of the other clinical abnormalities were observed in the maternal kindred.

mtDNA analysis
--------------

The suggestively maternal transmission of hypertension in this family implied the mitochondrial involvement and led us to analyze the mitochondrial genome of matrilineal relatives. For this purpose, the DNA fragments spanning the entire mtDNA of the proband II-6 were PCR amplified, and each fragment was purified and subsequently analyzed by direct sequence. As shown in [Table 3](#tbl3){ref-type="table"}, comparison of the resultant sequences with the revised Cambridge consensus sequence^[@bib26]^ identified the known hypertension-associated 4435A\>G mutation in the tRNA^Met^ gene^[@bib17]^ and other 41 known nucleoside changes, belonging to the Eastern--Asian haplogroup G2a1.^[@bib20]^ Of other mtDNA variants of the proband II-9, there were 12 polymorphisms in the D-loop region, 2 variants in the 12S rRNA gene, 1 variant in the 16S rRNA gene, the 5601C\>T mutation in the tRNA^Ala^ gene, the 12280A\>G mutation in the tRNA^Leu(CUN)^ gene, the 17 silent mutations and 6 missense mutations in protein encoding genes (<http://www.mitomap.org> or <http://www.genpat.uu.se/mtDB>).^[@bib13],\ [@bib27]^ These missense mutations were the 4833A\>G (122T\>A) in the *ND2* gene, the 8701A\>G (59T\>A)and 8860A\>G (112T\>A) in *A6* gene, the 10398A\>G (114T\>A) in the *ND3* gene, and the 14766C\>T (7T\>I) and 15326A\>G (194T\>A) in the *Cytb* gene. These variants in tRNAs, rRNAs and polypeptides were further evaluated by phylogenetic analysis of these variants and sequences from 16 vertebrates including mouse,^[@bib28]^ bovine,^[@bib29]^ and *Xenopus laevis*.^[@bib30]^ The conservation index (CI) was calculated by comparing the human nucleotide variants with 16 other vertebrates. CIs of these variants including the tRNA^Ala^ 5601C\>T and tRNA^Leu(CUN)^ 12280A\>G were \<70% CI, which was below the threshold level to be functionally significant in terms of mitochondrial physiology, as proposed by Wallace.^[@bib31]^ This suggests that these variants may not be functionally significant. Based on the nomenclature of mitochondrial haplogroups,^[@bib20]^ we used the mtDNA sequence variations of the Chinese proband to establish the haplogroup affiliation of his mtDNA. Here, mtDNA of this pedigree belonged to the Eastern--Asian halpogroup G2a1.

The known 4435A\>G mutation in the tRNA^Met^ gene, as shown in [Figure 2](#fig2){ref-type="fig"}, is located at immediately 3′ end to the anticodon, corresponding to the conventional position 37 of tRNA^Met^.^[@bib32]^ An adenine at this position is an extraordinarily conserved base in every sequenced methionine tRNA from bacteria to human mitochondria.^[@bib32],\ [@bib33]^ The nucleotide at the position 37 is more prone to modification than those at other places of tRNA.^[@bib34]^ The nucleotide modification at this position has been shown to have a pivotal role in the stabilization of tertiary structure and the biochemical function of tRNA.^[@bib34]^ To determine if the 4435A\>G mutation is present in homoplasmy, the fragments spanning the tRNA^Met^ gene were PCR-amplified and subsequently digested with *Nla*III. There was no detectable wild-type DNA in all available matrilineal relatives (data not shown), indicating that the 4435A\>G mutation was present in homoplasmy in these matrilineal relatives.

Discussion
==========

In the present study, we have performed the clinical, genetic and molecular characterization of a Han Chinese family with essential hypertension. The hypertension as a sole clinical phenotype was only present in all matrilineal relatives of this three-generation pedigree. Clinical and genetic evaluation revealed the variable severity and age at onset in hypertension. In particular, the age at onset of hypertension in the affected matrilineal relatives in this family varied from 31 to 65 years, with an average of 52 years. This result was comparable to those of other Chinese families with maternally transmitted hypertension.^[@bib14],\ [@bib15],\ [@bib16],\ [@bib17]^ Mutational analysis of mitochondrial genome in this family identified the tRNA^Met^ 4435A\>G mutation and other 35 variants belonging to the Eastern--Asian haplogroup G2a1.^[@bib20]^ On the other hand, the 4435A\>G mutation also occurred in the other mtDNA haplogroups B5a, D, M7a2 and J.^[@bib17],\ [@bib18],\ [@bib19],\ [@bib35]^ This suggested that the 4435A\>G mutation occurred sporadically and multiplied through evolution of the mtDNA. The 4435A\>G mutation was associated with essential hypertension in a Chinese family,^[@bib17]^ and other clinical abnormalities including Leber\'s hereditary optic neuropathy^[@bib18]^ and type 2 diabetes.^[@bib19]^ The occurrence of the 4435A\>G mutation in these genetically unrelated subjects affected by the hypertension suggests that this mutation is involved in the pathogenesis of hypertension.

It was anticipated that the 4435A\>G mutation resulted in a deficient nucleotide modification at position 37 of tRNA^Met^, thereby altering the structure and function of tRNA^Met^. Functional significance of the 4435A\>G mutation was supported by the fact that ∼40--50% reduction in the levels of tRNA^Met^ was observed in cells carrying the 4435A\>G mutation.^[@bib17],\ [@bib18]^ As a result, a failure in the tRNA^Met^ metabolism is responsible for the reduced rate of mitochondrial protein synthesis. Subsequently, these defects led to an impairment of the mitochondrial respiration chain function, reduction of ATP production and increase of reactive oxygen species production. These mitochondrial dysfunctions may contribute to the development of hypertension.^[@bib7],\ [@bib10],\ [@bib15],\ [@bib36],\ [@bib37],\ [@bib38]^ In particular, the impaired mitochondrial function could contribute to the characteristic age-related increase in blood pressure.^[@bib39]^ The homoplasmic form, mild mitochondrial dysfunction, late onset and incomplete penetrance of hypertension observed in this Chinese family carrying the 4435A\>G mutation suggest that the mutation is an inherited risk factor necessary for the development of hypertension but may by itself be insufficient to produce a clinical phenotype. Indeed, the incomplete penetrance of other clinical abnormalities arises from homoplasmic mtDNA mutations such as hypertension-associated mtDNA 4401A\>G mutation,^[@bib15]^ deafness-associated 12S rRNA 1555A\>G mutation^[@bib40]^ and Leber\'s hereditary optic neuropathy-associated *ND4* 11778G\>A mutation.^[@bib41]^ These homoplasmic mtDNA mutations only exhibited mild mitochondrial dysfunction.^[@bib15],\ [@bib16],\ [@bib40],\ [@bib42]^ The other modifier factors such as nuclear modifier genes, environmental and epigenetic factors, and personal lifestyles^[@bib39],\ [@bib43]^ may contribute to the development of hypertension in these subjects carrying the 4435A\>G mutation. In particular, the tissue specificity of this mutation is likely attributed to tissue-specific RNA modification or the involvement of nuclear modifier genes. The 4435A\>G mutation should be added to the list of inherited risk factors for future molecular diagnosis. Those who are positive for the 4435A\>G mutation should be warned that they are at risk for the development of hypertension and therefore pay attention to their personal lifestyles. In conclusion, our data support the previous observation that impaired mitochondrial function caused by the 4435A\>G tRNA^Met^ mutation was associated with essential hypertension. Therefore, our findings will be helpful for counseling families of maternally inherited hypertension.

This work was supported by National Institutes of Health (NIH) grants RO1DC05230 and RO1DC07696 from the National Institute on Deafness and Other Communication Disorders, a start-up fund from Zhejiang University to M-XG.

The authors declare no conflict of interest.

![The Chinese pedigree with hypertension. Affected individuals are indicated by filled symbols. Arrowhead denotes the proband.](ejhg2011111f1){#fig1}

![Identification of the 4435A\>G mutation in the mitochondrial tRNA^Met^ gene. (**a**) Partial sequence chromatograms of the tRNA^Met^ gene from affected individual II-6 and a married-in control II-7. An arrow indicates the location of the base changes at position 4435. (**b**) The location of the 4435A\>G mutation in the mitochondrial tRNA^Met^. The cloverleaf structure of human mitochondrial tRNA^Met^ is derived from Florentz *et al*^[@bib32]^ Arrowhead indicates the position of the 4435A\>G mutation.](ejhg2011111f2){#fig2}

###### Summary of clinical data for some members in a Chinese pedigree

  *Subjects*                          *Gender*  *Age of test (years)*   *Age of onset (years)*   *Systolic pressure (mm Hg)*   *Diastolic pressure (mm Hg)*    *IVST (mm) (6--12 mm)*   *LVMI (g/m*^*2*^)   *ECG*   *CR (μmol/l)*   *UR (μmol/l)*
  ---------------------------------- ---------- ----------------------- ------------------------ ----------------------------- ------------------------------ ------------------------ ------------------- ------- --------------- ---------------
  I-2                                    F      65                      65                       165                           110                                      ---                    ---           ---         ---             ---
  II-2[a](#t1-fn2){ref-type="fn"}        F      63                      60                       165                           110                                      ---                    ---           ---         ---             ---
  II-3[a](#t1-fn2){ref-type="fn"}        M      70                      65                       170                           95                                        9                   123.77          SB          84              5.1
  II-4[a](#t1-fn2){ref-type="fn"}        F      64                      31                       200                           100                                       10                   84.58          MI          64              6.3
  II-6[a](#t1-fn2){ref-type="fn"}        F      56                      46                       150                           96                                        9                    77.45           N          58              5.5
  II-8[a](#t1-fn2){ref-type="fn"}        F      53                      53                       150                           100                                       8                    85.71          MI          55              3.9
  II-9[a](#t1-fn2){ref-type="fn"}        M      60                      54                       190                           110                                       12                   72.59          LVH         70              5.5
  III-1[a](#t1-fn2){ref-type="fn"}       M      57                      54                       140                           90                                        10                   97.99           N          75              7.1
  III-3                                  M      48                      ---                      120                           80                                        8                    59.74           N          80              7.2
  III-4                                  M      46                      ---                      130                           80                                        10                  132.66          MI          66              5.8
  III-5                                  F      51                      51                       140                           95                                        9                    89.69          MI          48              4.6
  III-6                                  M      38                      ---                      125                           85                                       ---                    ---           ---         ---             ---
  III-7                                  M      38                      ---                      120                           75                                       ---                    ---           ---         ---             ---
  III-8                                  F      41                      ---                      130                           80                                        8                    97.15         ST-E         63              5.9
  III-9                                  F      30                      ---                      115                           85                                       ---                    ---           ---         ---             ---
  III-10                                 F      33                      ---                      125                           80                                       ---                    ---           ---         ---             ---
  III-11                                 M      26                      ---                      135                           75                                       ---                    ---           ---         ---             ---

Abbreviations: F, female, M, male; IVST, interventricular septal thickness; LVMI, left ventricular mass index; N, electrocardiography (ECG) was normal; LVH, ECG showed left ventricular hypertrophy; MI, myocardial ischemia; SB, sinus bradycardia; ST-E, ST segment elevation; CR, creatinine; UR, urea nitrogen.

These patients had antihypertension treatment. This table shows pre-treatment blood pressures.

###### Summary of laboratory examinations for some members of a Chinese family

  *Subjects*     *II-4*   *II-6*   *II-8*   *II-9*                *Chinese reference*
  ------------- -------- -------- -------- -------- ------------------------------------------------
  Therapy         Yes      Yes      Yes      Yes                          ---
  Alcohol          No       No       No      Yes                          ---
  Tobacco          No       No       No      Yes                          ---
  FPG, mmol/l     5.6      4.4      4.6      4.8                       3.90--6.10
  TC, mmol/l      5.22     4.3      5.68     3.8                       2.44--5.17
  TG, mmol/l      1.92     1.76     1.13     1.1                       0.40--1.70
  HDL, mmol/l     1.34     1.91     1.74     1.13                      1.16--1.42
  LDL, mmol/l     3.04     1.45     2.97     2.2                       2.10--3.10
  UA, μmol/l      415      268      226      358     214--488 (137--363)[a](#t2-fn2){ref-type="fn"}

Abbreviations: FPG, fasting blood glucose; TC, total cholesterol; TG, triglyceride; HDL, high-density lipoprotein cholesterol; LDL, low-density lipoprotein cholesterol; UA, uric acid.

Reference value especially for females.

###### mtDNA variants in one Han Chinese subject (II-6) with hypertension

  *Gene*           *Position*   *Replacement*          *Conservation H/M/B/X*[a](#t3-fn1){ref-type="fn"}   *Previously reported*[b](#t3-fn2){ref-type="fn"}
  ---------------- ------------ --------------------- --------------------------------------------------- --------------------------------------------------
  D-Loop           73           A to G                                                                                           Yes
                   152          T to C                                                                                           Yes
                   263          A to G                                                                                           Yes
                   310          T to CTC                                                                                         Yes
                   489          T to C                                                                                           Yes
                   16 223       C to T                                                                                           Yes
                   16 227       A to G                                                                                           Yes
                   16 272       A to G                                                                                           Yes
                   16 278       C to T                                                                                           Yes
                   16 319       G to A                                                                                           Yes
                   16 362       T to C                                                                                           Yes
                   16 519       T to C                                                                                           Yes
  12S rRNA         709          G to A                                      G/A/A/A                                              Yes
                   750          A to G                                      A/G/A/A                                              Yes
                   1438         A to G                                      A/A/A/G                                              Yes
  16S rRNA         2706         A to G                                      A/A/G/A                                              Yes
  tRNA^Met^        4435         A to G                                      A/A/A/A                                              Yes
  ND2              4769         A to G                                                                                           Yes
                   4833         A to G (Thr to Ala)                         T/I/I/L                                              Yes
                   5108         T to C                                                                                           Yes
  tRNA^Ala^        5601         C to T                                      C/C/C/G                                              Yes
  CO1              7028         C to T                                                                                           Yes
  CO2              7600         G to A                                                                                           Yes
  ATP6             8701         A to G (Thr to Ala)                         T/S/L/Q                                              Yes
                   8860         A to G (Thr to Ala)                         T/A/A/T                                              Yes
  CO3              9377         A to G                                                                                           Yes
                   9540         T to C                                                                                           Yes
                   9575         G to A                                                                                           Yes
  ND3              10 398       A to G (Thr to Ala)                         T/T/T/A                                              Yes
                   10 400       C to T                                                                                           Yes
  ND4              10 873       T to C                                                                                           Yes
                   11 719       G to A                                                                                           Yes
  tRNA^Leu(CUN)^   12 280       A to G                                      A/G/A/A                                              Yes
  ND5              12 705       C to T                                                                                           Yes
                   13 563       A to G                                                                                           Yes
                   14 034       T to C                                                                                           Yes
  ND6              14 569       G to A                                                                                           Yes
  CYB              14 766       C to T (Thr to Ile)                         T/S/T/S                                              Yes
                   14 783       T to C                                                                                           Yes
                   15 043       G to A                                                                                           Yes
                   15 301       G to A                                                                                           Yes
                   15 326       A to G (Thr to Ala)                         T/M/I/I                                              Yes

Concervation of amino acid for polypeptides or nucleotide for rRNAs, in human (H), mouse (M), bovine (B), and *Xenopus laevis* (X).

See [http//www.mitomap.org](http//www.mitomap.org) and <http://www.genpat.uu.se/mtDB/>.
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